Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CCND3 | P30281 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.46 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | GALR1 | P47211 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649390 | 0.92 | GALR2 (0.44) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL8068266 | 0.90 | MET (0.49) | CDK2CDK9GALR2GALR1JAK2 | |
| SCHEMBL3657530 | 0.86 | CTSC (0.47) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL3706813 | 0.82 | MET (0.54) | CCNKCCNA2CDK2CCND3CDK9 | |
| SCHEMBL3653329 | 0.80 | TGFBR1 (0.46) | EGFRERBB3 | |
| SCHEMBL3651458 | 0.79 | APP (0.48) | EGFRERBB3JAK2 | |
| SCHEMBL3655769 | 0.79 | GRM4 (0.41) | GALR2GALR1BRD4BCL6 | |
| SCHEMBL3654890 | 0.79 | RAF1 (0.47) | CCNA2CDK2EGFRERBB3JAK2 | |
| SCHEMBL3656271 | 0.78 | EGFR (0.47) | EGFRERBB3 | |
| SCHEMBL27797431 | 0.77 | GALR2 (0.46) | STK33FGFR3GALR2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2205317-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009044160-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HCRTR1, HCRTR2, RTN3 | CCNK 4280/4885CCNA2 4013/4885CDK2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.